Cytosorbents Corp
No SEC Form 4 filings for $CTSO in the last 30 days.
CytoSorbents (NASDAQ: CTSO) reported Q2 2026 revenue of $9.6 million, unchanged year over year. Gross margin rose to 73%. Operating loss fell 27% to $2.6 million, and net loss was $4.4 million ($0.07/share). Adjusted net loss improved 22% to $2.8 million. Cash burn was $0.4 million. The company also discussed sales trends and FDA regulatory plans.
Cytosorbents Corp (CTSO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622246d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update Highlighting Four Independent Drivers of Shareholder Value PRINCETON, N.J., August 6, 2026 — CytoSorbents Corpo
MARIANI PETER J (Chief Financial Officer) purchased 100,000 shares of Cytosorbents Corp (CTSO) at $0.44 on 2026-06-15.
Over the past 7 days, alphai's AI scored 2 news stories mentioning CTSO (Cytosorbents Corp). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent CTSO coverage spans earnings, insider activity and financial news.
The quarter shows improving profitability metrics and sharply lower cash burn, plus a stated path toward operating cash flow breakeven in 2H 2026.
The filing provides a near-term liquidity and margin trajectory signal, plus a stated path toward operating cash flow breakeven in 2H 2026.
Insider buying is a modest sentiment signal, but it is not a fundamental catalyst by itself.
Insider open-market buying by the CEO is a modest bullish signal, but it is not a fundamental catalyst like guidance, trials, or financing.
Earnings showed modest revenue growth and improving adjusted losses, but FDA’s added non-clinical/real-world requirements likely push DrugSorb-ATR approval timing into late 2026/early 2027.
alphai scores every news story that mentions CTSO with an AI model for sentiment and relevance, and aggregates insider trades from Cytosorbents Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
CytoSorbents (NASDAQ: CTSO) reported Q2 2026 revenue of $9.6 million, unchanged year over year. Gross margin rose to 73%. Operating loss fell 27% to $2.6 million, and net loss was $4.4 million ($0.07/share). Adjusted net loss improved 22% to $2.8 million. Cash burn was $0.4 million. The company also discussed sales trends and FDA regulatory plans.
6 min readCytosorbents Corp (CTSO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622246d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update Highlighting Four Independent Drivers of Shareholder Value PRINCETON, N.J., August 6, 2026 — CytoSorbents Corpo
6 min readMARIANI PETER J (Chief Financial Officer) purchased 100,000 shares of Cytosorbents Corp (CTSO) at $0.44 on 2026-06-15.
1 min readChan Phillip P. (Chief Executive Officer) purchased 261,469 shares of Cytosorbents Corp (CTSO) at an average of $0.40 ($0.40–$0.43, $0.10M total) across 2 trades over 2026-06-12 to 2026-06-15.
2 min readCytosorbents (CTSO) reported Q1 2026 revenue of $8.9 million, up 2% YoY, with direct international markets (excluding Germany) up 13% while Germany declined. Gross margin fell to 69% from 71%. Adjusted EBITDA loss narrowed to $2.2 million (vs. $2.7 million), as operating expenses dropped to $9.2 million. Net loss was $5.1 million ($0.08/share). FDA said DrugSorb-ATR needs additional non-clinical data and real-world evidence for a de novo submission, likely pushing timing to late 2026/early 2027.
6 min readCytoSorbents (CTSO) reported a wider net loss of $5.1 million in Q1 2026, an increase from $1.5 million in Q1 2025, despite a slight revenue increase to $8.9 million. The company's cash position of $6.3 million against $18.4 million in debt has raised "substantial doubt" about its ability to continue as a going concern for the next 12 months. CytoSorbents is implementing a cost reduction plan and seeking additional financing while pursuing FDA approval for its DrugSorb-ATR device.
4 min readImage source: The Motley Fool.Thursday, November 13, 2025 at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
3 min read
